Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-17
2010-12-07
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266240
Reexamination Certificate
active
07846936
ABSTRACT:
The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
REFERENCES:
patent: 6306874 (2001-10-01), Fraley et al.
patent: 6762180 (2004-07-01), Roth et al.
patent: 6794393 (2004-09-01), Fraley et al.
patent: 7019012 (2006-03-01), Himmelsbach et al.
patent: 7220750 (2007-05-01), Himmelsbach et al.
patent: 2002/0169180 (2002-11-01), Himmelsbach et al.
patent: 2002/0173509 (2002-11-01), Himmelsbach et al.
patent: 2003/0069299 (2003-04-01), Walter et al.
patent: 2003/0108545 (2003-06-01), Rockwell et al.
patent: 2003/0119819 (2003-06-01), Liang et al.
patent: 2003/0225079 (2003-12-01), Singer et al.
patent: 2004/0127453 (2004-07-01), Lyons et al.
patent: 2004/0176392 (2004-09-01), Roth et al.
patent: 2005/0043233 (2005-02-01), Stefanic et al.
patent: 2005/0085495 (2005-04-01), Soyka et al.
patent: 2006/0058311 (2006-03-01), Munzert et al.
patent: 2006/0100223 (2006-05-01), Himmelsbach et al.
patent: 2007/0027170 (2007-02-01), Soyka et al.
patent: 2007/0099918 (2007-05-01), Singer et al.
patent: 2007/0185091 (2007-08-01), Himmelsbach et al.
patent: 2008/0254040 (2008-10-01), Stefanic et al.
patent: 2009/0238828 (2009-09-01), Munzert et al.
patent: 2009/0306044 (2009-12-01), Solca et al.
patent: 2009/0306101 (2009-12-01), Solca et al.
patent: 2009/0306378 (2009-12-01), Schroeder et al.
patent: 2009/0318480 (2009-12-01), Solca
patent: 2010/0069414 (2010-03-01), Himmelsbach et al.
patent: 2010/0144639 (2010-06-01), Singer et al.
patent: 2 387 013 (2001-04-01), None
patent: 2 432 428 (2002-06-01), None
patent: 2 493 310 (2004-02-01), None
patent: 199 24 401 (2000-11-01), None
patent: 100 42 696 (2002-03-01), None
patent: 102 33 500 (2004-02-01), None
patent: 9723466 (1997-07-01), None
patent: 97/41844 (1997-11-01), None
patent: 98/54156 (1998-12-01), None
patent: 0038786 (2000-07-01), None
patent: 0078735 (2000-12-01), None
patent: 01/27081 (2001-04-01), None
patent: 01/32651 (2001-05-01), None
patent: 0172721 (2001-10-01), None
patent: 02/50043 (2002-06-01), None
patent: 02/070008 (2002-09-01), None
patent: 02092091 (2002-11-01), None
patent: 03/011837 (2003-02-01), None
patent: 03/022815 (2003-03-01), None
patent: 03026574 (2003-04-01), None
patent: 03/065995 (2003-08-01), None
patent: 03094921 (2003-11-01), None
patent: 2004096224 (2004-11-01), None
patent: 2005037824 (2005-04-01), None
patent: 2006018182 (2006-02-01), None
patent: 2007054550 (2007-05-01), None
patent: 2007054551 (2007-05-01), None
patent: 2007085638 (2007-08-01), None
patent: 2008034776 (2008-03-01), None
patent: 2009147218 (2009-12-01), None
Jones, H. E. et al; “Effect of an EGF-R Selective Tyrosine Kinase Inhibitor and an Anti-Androgen on LNCaP Cells: Identification of Divergent Growth Regulatory Pathways”; The Prostate 49:38-47 (2001) XP008022176.
International Search Report for PCT/EP2004/004363 mailed on Nov. 5, 2004.
Abstract in English for DE10042696, copyright 2006.
Abstract in English for DE10233500, copyright 2006.
Abstract in English for DE19924401, 2000.
Sielecki et al., “Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation”, Journal of Medicinal Chemistry, 2000, 43 (1), p. 1-18.
Bramson et al., “Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray crystallographic Analysis”, Journal of Medicinal Chemisty, 2001, 44 (25), p. 4339-4358.
Hennequin et al., “Novel 4-Anilinoquinazolines with c-7 Basic Side Chains: Design and Structure Activity Relationship of a series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors”, Journal of Medicinal Chemistry, 2002, 45 (6), p. 1300-1312.
Manley et al., “Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Recepto Kinase Inhibitors”, Journal of Medicinal Chemistry, 2002, 45 (26), p. 5687-5693.
Baum Anke
Hilberg Frank
Solca Flavio
van Meel Jacobus C. A.
Anderson James D
Boehringer Ingelheim International GmbH
Bottino Anthony P.
Morris Michael P.
LandOfFree
Combinations for the treatment of diseases involving cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations for the treatment of diseases involving cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations for the treatment of diseases involving cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4213921